EXEL News and Press, Exelixis Inc. From 04/29/24

2024-04-29 17:20:42 ET More on Exelixis Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024 Exelixis, Inc. (EXEL) Q4 2023 Earnings Call Transcript Exelixis slips as Barclays downgrades on lack of catalysts Exelixis Q4 2023 Earnings Pre...

2024-04-27 07:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are notorious for being some of the most volatile and unpredictable on the market. With clinical trials and FDA approvals creating potential leaps or falls in what seems like...

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2024 financial results will be released on Tuesday, April 30, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exe...

2024-04-11 10:10:03 ET More on Exelixis Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024 Exelixis, Inc. (EXEL) Q4 2023 Earnings Call Transcript Exelixis: 2024 Looking Good In The Mid-Term Exelixis Q4 2023 Earnings Preview Se...

2024-04-11 09:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-04 11:12:55 ET More on Health Care Select Sector SPDR: XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli...

2024-04-01 11:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-28 14:54:46 ET Summary Exelixis has seen strong revenue growth from its drug cabozantinib, but its net income has been inconsistent. The company is facing patent challenges from generics, with the potential for a generic version of cabozantinib to launch in 2026. Exeli...

2024-03-27 11:19:59 ET More on S&P 1000 Index, S&P 500 Index, etc. Heightened Threat Of Japanese Intervention Pushes Greenback Away From JPY152 What Are Markets Pricing In? The Peak Fed Dovishness - That's Negative For The Stock Market Nasdaq, S&P...

2024-03-25 13:07:32 ET Summary M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot ...